Bivariate analysis of ATG exposure association with NRM, relapse, and DFS with controlling for other factors
| Variable and categories . | n . | NRM . | SHR estimate∗ (95% CI) . | P value . | Relapse . | SHR estimate∗ (95% CI) . | P value . | 1-DFS . | HR estimate† (95% CI) . | P value . |
|---|---|---|---|---|---|---|---|---|---|---|
| n events . | n events . | n events . | ||||||||
| Univariate | ||||||||||
| ATG exposure quadrant | ||||||||||
| Q1 (before >50; after <12) | 52 | 3 | 1.0 | .1 | 3 | 1.0 | <.001 | 6 | 1.0 | <.001 |
| Nonoptimal (Q2-4) | 111 | 15 | 2.82 (0.82-9.78) | 28 | 5.32 (1.62-17.53) | 43 | 4.06 (1.72-9.54) | |||
| Bivariate controlling for age (<10 y vs ≥10 y) | ||||||||||
| ATG exposure quadrant | ||||||||||
| Q1 (before >50; after <12) | 52 | 3 | 1.0 | .07 | — | — | — | — | — | — |
| Nonoptimal (Q2-4) | 111 | 15 | 3.1 (0.91-10.95) | |||||||
| Bivariate controlling for MRD status (negative vs positive) | ||||||||||
| ATG exposure quadrant | ||||||||||
| Q1 (before >50; after <12) | 52 | — | — | — | 3 | 1.0 | .003 | 6 | 1.0 | .001 |
| Nonoptimal (Q2-Q4) | 111 | 28 | 6.33 (1.91-20.97) | 43 | 4.24 (1.79-10.03) | |||||
| Bivariate controlling for donor type (parent vs sibling) | ||||||||||
| ATG exposure quadrant | ||||||||||
| Q1 (before >50; after <12) | 52 | 3 | 1.0 | .11 | — | — | — | — | — | — |
| Nonoptimal (Q2-Q4) | 111 | 15 | 2.76 (0.8-9.6) | |||||||
| Bivariate controlling for CMV serostatus (all others vs R+/D−) | ||||||||||
| ATG exposure Q3 | ||||||||||
| Q1 (before >50; after <12) | 52 | 3 | 1.0 | .14 | 3 | 1.0 | .007 | 6 | 1.0 | .002 |
| Nonoptimal (Q2-Q4) | 111 | 15 | 2.59 (0.74-9.05) | 28 | 5.11 (1.55-16.86) | 43 | 3.84 (1.63-9.05) | |||
| Bivariate controlling for CD34 dose (<15 × 106/kg vs ≥15 × 106/kg) | ||||||||||
| ATG exposure quadrant | ||||||||||
| Q1 (before >50; after <12) | 52 | — | — | — | — | — | — | 6 | 1.0 | .002 |
| Nonoptimal (Q2-Q4) | 111 | 43 | 3.99 (1.7-9.4) |
| Variable and categories . | n . | NRM . | SHR estimate∗ (95% CI) . | P value . | Relapse . | SHR estimate∗ (95% CI) . | P value . | 1-DFS . | HR estimate† (95% CI) . | P value . |
|---|---|---|---|---|---|---|---|---|---|---|
| n events . | n events . | n events . | ||||||||
| Univariate | ||||||||||
| ATG exposure quadrant | ||||||||||
| Q1 (before >50; after <12) | 52 | 3 | 1.0 | .1 | 3 | 1.0 | <.001 | 6 | 1.0 | <.001 |
| Nonoptimal (Q2-4) | 111 | 15 | 2.82 (0.82-9.78) | 28 | 5.32 (1.62-17.53) | 43 | 4.06 (1.72-9.54) | |||
| Bivariate controlling for age (<10 y vs ≥10 y) | ||||||||||
| ATG exposure quadrant | ||||||||||
| Q1 (before >50; after <12) | 52 | 3 | 1.0 | .07 | — | — | — | — | — | — |
| Nonoptimal (Q2-4) | 111 | 15 | 3.1 (0.91-10.95) | |||||||
| Bivariate controlling for MRD status (negative vs positive) | ||||||||||
| ATG exposure quadrant | ||||||||||
| Q1 (before >50; after <12) | 52 | — | — | — | 3 | 1.0 | .003 | 6 | 1.0 | .001 |
| Nonoptimal (Q2-Q4) | 111 | 28 | 6.33 (1.91-20.97) | 43 | 4.24 (1.79-10.03) | |||||
| Bivariate controlling for donor type (parent vs sibling) | ||||||||||
| ATG exposure quadrant | ||||||||||
| Q1 (before >50; after <12) | 52 | 3 | 1.0 | .11 | — | — | — | — | — | — |
| Nonoptimal (Q2-Q4) | 111 | 15 | 2.76 (0.8-9.6) | |||||||
| Bivariate controlling for CMV serostatus (all others vs R+/D−) | ||||||||||
| ATG exposure Q3 | ||||||||||
| Q1 (before >50; after <12) | 52 | 3 | 1.0 | .14 | 3 | 1.0 | .007 | 6 | 1.0 | .002 |
| Nonoptimal (Q2-Q4) | 111 | 15 | 2.59 (0.74-9.05) | 28 | 5.11 (1.55-16.86) | 43 | 3.84 (1.63-9.05) | |||
| Bivariate controlling for CD34 dose (<15 × 106/kg vs ≥15 × 106/kg) | ||||||||||
| ATG exposure quadrant | ||||||||||
| Q1 (before >50; after <12) | 52 | — | — | — | — | — | — | 6 | 1.0 | .002 |
| Nonoptimal (Q2-Q4) | 111 | 43 | 3.99 (1.7-9.4) |